S-1/A: Carmell Corp Files Amendment for Resale of 1.33 Million Common Shares After Private Placement

Carmell Corporation has filed an amendment to its registration statement for the resale of up to 1,331,452 shares of common stock by selling stockholders following a private placement.

Summary

• Carmell Corporation has filed an amendment to a registration statement for the offer and resale of up to 1,331,452 shares of its common stock.
• These shares were previously issued to selling stockholders through a Securities Purchase Agreement dated April 4, 2024, in a private placement that closed on April 11, 2024.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• The selling stockholders may sell shares at fixed prices, market prices, related to market prices, or negotiated prices.
• Carmell's common stock is listed on The Nasdaq Capital Market under the symbol CTCX, with the last reported sale price on May 28, 2024, at $2.53 per share.
• The company is classified as a smaller reporting company and an emerging growth company, which allows for certain reduced reporting requirements.
• On March 26, 2024, the company completed the sale of its subsidiary, Axolotl Biologix, LLC (AxoBio), to its former stockholders.
• The consideration for the AxoBio sale included the return of 3,845,337 shares of the company's common stock and 4,243 shares of Series A Convertible Voting Preferred Stock, as well as the cancellation of $8 million in notes payable.
• The company is focused on bio-aesthetics, utilizing the Carmell Secretome to support skin and hair health, and is also developing regenerative bone and tissue healing products.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the focus on a growing market and the elimination of debt through the AxoBio sale, the company's financial struggles and going concern warning weigh heavily on the sentiment.

Positives

• The sale of AxoBio eliminates debt and earnout obligations, simplifying the company's financial structure.
• The company is focusing on its bio-aesthetics business, which has potential for growth.

Negatives

• The company will not receive any proceeds from the resale of the 1,331,452 shares.
• The company is reliant on the selling stockholders to sell the shares.

Risks

• The company has limited experience as a commercial company.
• The company may require additional capital to support its growth plans.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company faces substantial competition.
• The price of the company's common stock may be volatile.
• The company may be involved in litigation that may materially adversely affect it.

Future Outlook

The company plans to launch its line of cosmetic skincare products and is exploring potential international markets.

Industry Context

The document notes that the skincare and haircare markets are expected to grow at a 6.4% compound annual growth rate, and the aesthetics market is growing faster than pharmaceuticals.

Legal Proceedings

• Puritan Partners LLC has filed a complaint against the company related to the Convertible Notes and Convertible Note Warrants.

Related Party Transactions

• The document mentions related party loans and transactions with OrthoEx and Ortho Spine Companies, LLC.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of new shares.
• Employees may be affected by potential cost-cutting measures.
• Customers may benefit from the launch of new cosmetic skincare products.

Next Steps

• The selling stockholders may offer and sell shares of common stock from time to time.
• The company plans to launch its line of cosmetic skincare products.

Key Dates

Keywords

common stock, resale, private placement, AxoBio, Carmell Corporation, bio-aesthetics, regenerative medicine